Temozolomide – Just a Radiosensitizer?
Radiation concomitant with the DNA methylating drug temozolomide (TMZ) is the gold standard in the treatment of glioblastoma. In this adjuvant setting, TMZ is regarded to be a radiation sensitizer. However, similar to ionising radiation, TMZ induces DNA double-strand breaks and is itself a potent tr...
Main Authors: | Bernd Kaina, Lea Beltzig, Herwig Strik |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.912821/full |
Similar Items
-
A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
by: Rui-Chao Chai, et al.
Published: (2019-09-01) -
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
by: Melguizo Consolación, et al.
Published: (2012-12-01) -
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
by: Chao Duan, et al.
Published: (2024-08-01) -
Efficacy of Whole-Ventricular Radiotherapy in Patients Undergoing Maximal Tumor Resection for Glioblastomas Involving the Ventricle
by: Kyung Hwan Kim, et al.
Published: (2021-09-01) -
Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy. Comment on Strobel et al., Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. <i>Biomedicines</i> 2019, <i>7</i>, 69
by: Bernd Kaina
Published: (2019-11-01)